Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:05:42 2024-04-25 pm EDT			5-day change	1st Jan Change
21.02 ^USD	-0.83%		-3.08%	-7.49%

Apr. 12	Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	MT
Apr. 04	Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	MT

Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 08:01 am EDT

Aerovate Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 11.99 million compared to USD 5.78 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 23.8 a year ago.
For the six months, net loss was USD 22.9 million compared to USD 8.56 million a year ago. Basic loss per share from continuing operations was USD 0.94 compared to USD 35.29 a year ago.

Latest news about Aerovate Therapeutics, Inc.

Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	Apr. 12	MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	Apr. 04	MT
Aerovate Therapeutics Q4 Loss Widens	Mar. 25	MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	Mar. 21	MT
Aerovate Therapeutics, Inc. Announces Board Changes	Mar. 06	CI
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing	Dec. 08	MT
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing	Nov. 30	MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension	Nov. 20	MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	Nov. 20	CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating	23-08-15	MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors	23-07-11	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Small Cap Comp Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell Microcap Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 3000E Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2500 Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 3000 Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) dropped from Russell 2000 Value Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell Microcap Growth Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 3000E Growth Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 2500 Growth Index	23-06-23	CI
Aerovate Therapeutics, Inc.(NasdaqGM:AVTE) added to Russell 3000 Growth Index	23-06-23	CI

Chart Aerovate Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.2 USD

Average target price

44.67 USD

Spread / Average Target

+110.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AEROVATE THERAPEUTICS, INC.	-7.49%	591M
IQVIA HOLDINGS INC.	+0.79%	43.84B
MODERNA, INC.	+5.83%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+5.89%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.96%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.99%	12.29B
MEDPACE HOLDINGS, INC.	+25.94%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.72%	11.15B

Other Biotechnology & Medical Research